News

We’re seeking individuals aged 40 to 60 with stage 3 or 4 periodontitis to participate in a Melbourne-based clinical trial.

Help us test a promising vaccine administered over a 2-month period that could revolutionize periodontal disease treatment.

Denteric is pleased to advise that it has completed recruitment and dosing of 3 cohorts in its Phase I GPV381 clinical trial. The company is now planning an additional cohort in people with confirmed periodontal disease.

Denteric is pleased to announce that its first subjects have been dosed today in its first in human safety study of GPV381, a therapy designed to treat severe periodontal disease.  The phase 1 study will assess safety and tolerability of the therapy in healthy subjects and is being conducted at Nucleus Networks Phase I Unit in Melbourne.

Round one provided support to Denteric, an early-stage biotech developing therapies targeting  Porphyromonas gingivalis (Pg) related diseases – initially focused on severe periodontal disease.

Recent success with Pfizer and Moderna vaccines to Covid-19 has proven efficacy of mRNA vaccines for viruses, but little is known about using mRNA against bacterial pathogens, which are equally abundant.

Denteric co-founder Professor Reynolds has been recognised for his outstanding achievement in translating scientific discoveries into globally successful products that prevent and treat oral disease.

CSL-backed biotech company Denteric has closed a $14 million funding round, enabling it to develop a vaccine for a gum disease that affects one in three adults globally, with a human clinical trial expected within three years.

A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd.